Xin Lang Cai Jing·2025-09-18 05:32Core Viewpoint - 康龙化成 has shown significant stock price appreciation and financial performance, with a notable increase in revenue but a decline in net profit [1][2]. Financial Performance - As of June 30, 康龙化成 reported a revenue of 64.41 billion yuan for the first half of 2025, representing a year-on-year growth of 14.93% [2]. - The net profit attributable to shareholders for the same period was 7.01 billion yuan, reflecting a decrease of 37.00% compared to the previous year [2]. Stock Performance - 康龙化成's stock price increased by 41.96% year-to-date, with a 56.85% rise over the past 60 days [1]. - The stock was trading at 36.20 yuan per share, with a market capitalization of 643.71 billion yuan as of September 18 [1]. Shareholder Information - The number of shareholders increased to 87,900 as of June 30, 2025, marking a 10.12% rise [2]. - The top ten circulating shareholders include 中欧医疗健康混合A and 香港中央结算有限公司, with varying changes in their holdings [3]. Business Segmentation - 康龙化成's main business segments include laboratory services (60.43%), CMC services (21.58%), clinical research services (14.58%), and other services [1].